In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family

Tissue Antigens

Volumn 54, Issue 6, 1999, Pages 597-602

  Di Noto, R ^a   Boccuni, P ^a   Costantini, S ^a   Dello Russo, A ^a   Lo Pardo, C ^a   Copia, C ^a   Annunziata, M ^a   Cimino, R ^a   Ferrara, F ^a   Del Vecchio, Luigi ^a,b  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Acute myeloid leukemia; Acute promyelocytic leukemia; AML; APL; Apoptosis; Arsenic trioxide; As2O3; CD66c; CEA family

Indexed keywords

ARSENIC TRIOXIDE; CARCINOEMBRYONIC ANTIGEN; CD11B ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CD66C ANTIGEN; DIFFERENTIATION ANTIGEN; HERMES ANTIGEN; INTEGRIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL ADHESION MOLECULES; CELL MEMBRANE; EPITOPES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TUMOR CELLS, CULTURED;

EID: 0033391403     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.1999.540610.x     Document Type: Article

References (22)

1. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/ PML proteins. Blood 1996: 88: 1052-61.
2. 2. Chen GQ, Shi XG, Tang W et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997: 89: 3345-53.
3. 3. Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997: 89: 3354-60.
4. 4. Shao W, Fanelli M, Ferrara FF et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998: 90: 124-33.
5. 5. Zhu J, Koken MH, Quignon F et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997: 94: 3978-83.
6. 6. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998: 17: 61-70.
7. 7. Kansas GS, Muirhead MJ, Dailey MO. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 1990: 76: 2483-92.
8. 8. Schiavone EM, Lo Pardo C, Di Noto R et al. Expression of the leukocyte common antigen (LCA, CD45) isoforms RA and RO in acute haematological malignancies: possible relevance in the definition of new overlap points between normal and leukaemic haemopoiesis. Br J Haematol 1995: 91: 899-906.
9. 9. Jennings DC, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997: 90: 2863-92.
10. 10. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989: 57: 327-34.
11. 11. Kuijpers TW, Hoogerwerf M, van der Laan L et al. CD66 nonspecific cross-reacting antigens are involved in neutrophil adherence to cytokine-activated endothelial cells. J Cell Biol 1992: 118: 457-66.
12. 12. Hauck CR, Meyer TF, Lang F, Gulbins E. CD66-mediated phagocytosis of Opa52 Neisseria gonorrhoeae requires a Src-like tyrosine kinase-and Rac1-dependent signalling pathway. EMBO J 1998: 17: 443-54.
13. 13. Pinto A, Gattei V, Soligo D, Parravicini C, Del Vecchio L. New molecules burst at the leukocyte surface. Leukemia 1994: 8: 347-58.
14. 14. Skubitz KM, Grunert F, Jantscheef P, Kuroki M, Skubitz APN. CD66 family Workshop Panel report. In: Kishimoto T, ed. Leukocyte Typing VI. New York: Garland Publishing, Inc, 1997: 992-1000.
15. 15. Boccuni P, Di Noto R, Lo Pardo C et al. CD66c antigen expression is myeloid-restricted in normal bone marrow but is a common feature of CD10+ early-B cell malignancies. Tissue Antigens 1998: 52: 1-6.
16. 16. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985: 103: 620-9.
17. 17. Bennett JM, Catovsky D, Daniel MT et al. A variant form of acute hypergranular promyelocytic leukaemia (M3). Br J Haematol 1980: 44: 169-170.
18. 18. Di Noto R, Lo Pardo C, Schiavone EM et al. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma 1996: 21: 201-9.
19. 19. Di Noto R, Schiavone EM, Lo Pardo C et al. Differential regulation of GPI-linked molecules on leukaemic promyelocytes treated in vitro with all-trans retinoic acid. Br J Haematol 1996: 93: 392-3.
20. 20. Kitamura K, Kiyoi H, Yoshida H, et al. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer Chemother Pharmacol 1997: 40 (Suppl): 36-41.
21. 21. Gianni M, Koken MHM, Chelbi-Alix MK et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998: 91: 4300-10.
22. 22. Skubitz KM, Campbell KD, Ahmed K, Skubitz APN. CD66 family members are associated with tyrosine kinase activity in human neutrophils. J Immunol 1995: 155: 5382-90.